Phospholipase Signaling in Breast Cancer

Adv Exp Med Biol. 2021:1187:23-52. doi: 10.1007/978-981-32-9620-6_2.

Abstract

Breast cancer progression results from subversion of multiple intra- or intercellular signaling pathways in normal mammary tissues and their microenvironment, which have an impact on cell differentiation, proliferation, migration, and angiogenesis. Phospholipases (PLC, PLD and PLA) are essential mediators of intra- and intercellular signaling. They hydrolyze phospholipids, which are major components of cell membrane that can generate many bioactive lipid mediators, such as diacylglycerol, phosphatidic acid, lysophosphatidic acid, and arachidonic acid. Enzymatic processing of phospholipids by phospholipases converts these molecules into lipid mediators that regulate multiple cellular processes, which in turn can promote breast cancer progression. Thus, dysregulation of phospholipases contributes to a number of human diseases, including cancer. This review describes how phospholipases regulate multiple cancer-associated cellular processes, and the interplay among different phospholipases in breast cancer. A thorough understanding of the breast cancer-associated signaling networks of phospholipases is necessary to determine whether these enzymes are potential targets for innovative therapeutic strategies.

Keywords: Breast cancer; Cell signaling; Metastasis; Phospholipases; Phospholipid; Proliferation.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms*
  • Humans
  • Phospholipase D* / metabolism
  • Phospholipases
  • Phospholipids
  • Signal Transduction
  • Tumor Microenvironment
  • Type C Phospholipases / metabolism

Substances

  • Phospholipids
  • Phospholipases
  • Type C Phospholipases
  • Phospholipase D